Curriculum Vitae

Personal information

Teresa Cejalvo

Work experience

1. Employer: Spanish Agency of Medicines and Medical Devices
   - Start date: 042022
   - Position: Quality Assessor of biological human medicinal products, at the Biological Products, Advanced Therapies and Biotechnology Division
   - Activities: Assessment of clinical trials, scientific advices, and other regulatory procedures for biotechnological products and advanced therapies.
   - Country: Spain
2. Employer: Universidad Alfonso X El sabio
   - Start date: 062020
   - End date: 042022
   - Position: Senior scientist
   - Activities: Management of different projects in therapeutic in veterinary. Cell therapy
   - Country: Spain
3. Employer: "Fundación imasdoce" Hospital Universitario Doce de Octubre
   - Start date: 022018
   - End date: 022020
   - Position: Postdoctoral researcher
   - Activities: Neuro_oncology.
   - Country: Spain
4. Employer: Instituto de Salud Carlos III
   - Start date: 032014
   - End date: 032017
   - Position: Postdoctoral Researcher
   - Activities: Immunotherapy, Oncolytic virus.
   - Country: Spain
5. Employer: Universidad Complutense de Madrid
   - Start date: 022010
   - End date: 052013
   - Position: Superior Technician at Cytometry and Microscopy Center
   - Activities: Flow Cytometry and Microscopy specialist. Immunology. Research in thymus development.
   - Country: Spain
6. Employer: Universidad Complutense de Madrid
   - Start date: 082005
   - End date: 082009
   - Position: PhD student
   - Activities: Immunology. Thymus development. Eph and ephrins.
   - Country: Spain

Education and training

1. PhD Biological Sciences
   - Date: 062011
   - Organisation: Universidad Complutense de Madrid
   - Country: Spain
2. Bachelor degree in Sciences (Biological)
   - End date: 062003
   - Organisation: Universidad Complutense de Madrid
   - Country: Spain

Additional information

Publications

1. Rodriguez L, de Felipe P, Martín R, Martínez J, Ordoñez D, Rojo S, Martínez JF, Rincón E, Cejalvo T, Izquierdo I, Montanuy I, Timón M. The coming age of gene therapy for the treatment of human disease: A regulatory perspective. Hum Gene Therapy. 2025
2. Morales-Molina A, Rodriguez-Milla MÁ, Gambera S, Cejalvo T, de Andrés B, Gaspar ML, García-Castro J. Toll-like Receptor Signaling-deficient Cells Enhance Antitumor Activity of Cell-based Immunotherapy by Increasing Tumor Homing. Cancer Res Commun. 2023 Mar 1;3(3):347-360.
3. Segura_Collar B, Garranzo_Asensio M, Herranz B, Hernández_SanMiguel E, Cejalvo T, Casas BS, Matheu A, Pérez_Núñez Á, Sepúlveda_Sánchez JM, Hernández_Laín A, Palma V, Gargini R, Sánchez_Gómez P. Tumor_derived pericytes driven by EGFR mutations govern the vascular and immune microenvironment of gliomas. Cancer Res. 2021 Feb 16:canres.3558.2020.
4. Cejalvo T, Gargini R, Segura_Collar B, Mata_Martínez P, Herranz B, Cantero D, Ruano Y, García_Pérez D, Pérez_Núñez A, Ramos A, Hernández_Laín A, Martín_Soberón M C, Sánchez_Gómez P, Sepúlveda_Sánchez JM, Immune Profiling of Gliomas Reveals a Connection with IDH1/2 Mutations, Tau Function and the Vascular Phenotype. Cancers, Nov 2020. 2;12(11): E3230.
5. Gómez A, Sardón D, Cejalvo T, Vázquez F, García_Castro J, Perisé_Barrios AJ. Biodistribution Analysis of Oncolytic Adenoviruses in Canine Patient Necropsy Samples Treated with Cellular Virotherapy. Mol Ther Oncolytics. 2020 Aug 14;18:525_534

6. Rodríguez_Milla MÁ, Morales_Molina A, Perisé_Barrios AJ, Cejalvo T, García_Castro J. AKT and JUN are differentially activated in mesenchymal stem cells after infection with human and canine oncolytic adenoviruses.Cancer Gene Ther. 2020 May
7. Hernández_San Miguel E, Gargini R, Cejalvo T, Segura B, Hortigüela R, Núñez_Hervada P Manuel Sepúlveda J.; Hernández_Laín A.; Pérez_Núñez A.; Sanz E; Sanchez_Gómez P.. Ocoxin modulates cancer stem cells and M2_macrophage polarization in glioblastoma. Oxid. Med. Cell. Longev 2019/9719730.
8. Morales_Molina A. Gambera S; Cejalvo T; Moreno R; Rodriguez_Milla MA, Perise_Barrios AJ; García_Castro J, Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice.Cancer Immunology Immunotherapy. 67 _ 10, pp. 1589 _ 1602. 2018.
9. Cejalvo T, Perisé J; del Portillo I; Laborda E; Rodriguez MA; Cubillo I; García –Castro J; 2018. Remission of spontaneous canine tumors after systemic cellular viroimmunotherapy. Cancer Research
10. Rincón E; Cejalvo T; Kanojia D; Alfranca A; Rodriguez_Milla MA; Gil_Hoyos R; Han Yu; Zhang L; Alemany R; Lesniak MS; García_Castro J. 2017. Mesenchymal Stem Cell Carriers Enhance Antitumor Efficacy of Oncolytic Adenoviruses in an Immunocompetent Mouse Model. Oncotarget.
11. Muñoz JJ ;Cejalvo T, Tobajas E, Fanlo L, Cortés A, Zapata AG. 2015. 3D immunofluorescence analysis of early thymic morphogenesis and medulla development. Histology and Histopathology. Volumen: 30(5):Páginas, inicial: 589 final:599.
12. Cejalvo T, JJ Muñoz; E Tobajas; D Alfaro; J García_Ceca; A G Zapata; et al. (6/1). 2014. Conditioned deletion of ephrinB1 and/or ephrinB2 in either thymocytes or thymic epithelial cells alters the organization of thymic medulla and favors the appearance of thymic epithelial cysts.The Journal of Immunology. 143_(5), pp.517_529.
13. Cejalvo T;Muñoz JJ; Tobajas E; Fanlo L; Alfaro D; Garcia_Ceca JJ; Zapata AG et al. (7/1). 2013. Ephrin_B dependent TEC_Thymocyte interactions are necessary for correct T cell differentiation and thymus histology organization: Relevance for thymic cortex development. The Journal of Immunology. 15_190(6), pp.2670_2681.
14. Muñoz JJ; Cejalvo T; E Tobajas; L Fanlo; A Cortés; A G Zapata. et al. (6/2). 2011. Eph_ephrin_mediated interactions in the thymus. Neuroimunomodulation. 18(5), pp.271_280. 15. Alfaro D; Muñoz JJ; García_Ceca J; Cejalvo T; Jiménez E; Zapata AG et al. (6/4). 2011. The Eph/ephrinB signal balance determines the pattern of T_cell maturation in the thymus. Immunol Cell Biol. 89(8), pp.844_852.
15. Stimamiglio MA; Jiménez E; Silva_Barbosa SD; Alfaro D; García_Ceca JJ; Muñoz JJ; Cejalvo T; Savino W; Zapata AG. 2010. EphB2_mediated interactions are essential for proper migration of T_cell progenitors during fetal thymus colonization. Journal of Leukocyte Biology. 88(3), pp.483_494.
16. Varas, A.; Sacedon, R.; R.; Hidalgo, L.; Martinez, V. G.; Valencia, J.; Cejalvo, T.; Hernández_Lopez, C.; Zapata, A;Vicente, A; et al. (9/6). 2009. Interplay of BMP4 and IL7 on human intrathymic precursor cells. Cell Cycle. 15;8 (24), pp.4119_4126.
17. García_Ceca J;Jiménez E; Alfaro D; Cejalvo T; Muñoz JJ; Zapata AG et al. (6/4). 2009. Cell_autonomous role of EphB2 and EphB3 receptors in the thymic epithelial cell organization.Eur J Immunol. 39(10), pp.2916_2924.
18. García_Ceca J;Jiménez E; Alfaro D; Cejalvo T; Chumley MJ; Henkemeyer M; Muñoz JJ; Zapata AG. 2009. On the role of Eph signalling in thymus histogenesis; EphB2/B3 and the organizing of the thymic epithelial network.Int J Dev Biol.53(7), pp.971_982.
19. Muñoz JJ; García_Ceca J; Alfaro D; Stimamiglio MA; Cejalvo T; Jiménez E; Zapata AG (7/5). 2009. Organizing the thymus gland.Ann N Y Acad Sci.Feb;1153. Review., pp.14_19.
20. Alfaro, D., Muñoz JJ, García_Ceca JJ, Cejalvo T, Jimenez E, Zapata A. 2008. Alterations in the thymocyte phenotype of Eph B_deficient mice largely affect the double negative cell compartment.Immunology,. 125, pp.131_143.
21. Cejalvo T;Sacedón R; Hernández_López C; Diez B; Gutiérrez_Frías C; Valencia J; Zapata AG; Varas A; Vicente A et al. (9/1). 2007. BMP2/4 signalling pathway components are expressed in the human thymus and inhibit early T_cell development. Immunology. 121, pp.94_104.
22. Alfaro D;García_Ceca JJ; Cejalvo T; Jiménez E; Jenkinson EJ; Anderson G,; Muñoz JJ and Zapata, A (9/4). 2007. EphrinB1_EphB Signalling Regulates Thymocyte_Epithelium Interactions Involved in Functional T cell Development. Eur Journal of Immunology. 37, pp.2596_2605.
23. Zapata A; Cejalvo T; Gutierrez_Frías C; Cortés A et al. (5/3). 2005. Ontogeny of the Immune System of Fish. Fish and shellfish Immunology. 20, pp.126_136.
24. Sacedón R; Díez B; Núñez V; Hernández_López C; Gutierrez_Frías C; Cejalvo T; Outram SV; Crompton T; Zapata AG; Vicente A; Varas A et al. (11/6). 2005. Sonic Hedgehog is produced by follicular dendritic cells and protects germinal center B cells from apoptosis. Journal of Immunology. 174, pp.1456_1461.
25. Gutierrez_Frías C;Sacedón R; Hernández_López C; Cejalvo T; Crompton T; Zapata AG; Varas A; Vicente A et al. (8/4). 2004. Sonic Hedgehog Regulates Early Human Thymocyte Differentiation by Counteracting the IL_7_induced Development of CD34+ Precursor Cells. Journal of Immunology. 173, pp.5046_5053.
26. Sacedón R; Gutierrez_Frias C; Hernández_López C; Cejalvo T; Diez B; Crompton T; Zapata AG; Varas A; Vicente A. et al. 2004. Expression and function of Hedgehog proteins in the human thymus. Immunology 2004. Medimod s.r.l.. pp.375_378. Capítulo de libro.

Projects

Memberships

Other Relevant Information

Patents Inventores: García_Castro J, Cejalvo T, Perise_Barrios J, Stimamiglio S, Alvaro M Título: Combination product comprising a modified mesenchymal stem cell and an antigenic Substance Ref.: 902 072 Spanish Patent Application P201731066